In addition, this meta-analysis included a large proportion of melanomas (8%); these cancers are known to demonstrate consistently high PD-L1 expression and therefore could impact on the conclusions of PD-L1 as a biomarker of ICPI efficacy in other cancer sites (74). Here, CD274 is linked to melanoma.